Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04321616
Other study ID # 118684
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 28, 2020
Est. completion date November 2020

Study information

Verified date April 2020
Source Oslo University Hospital
Contact Paul Aukrust, MD, Professor
Phone 0047 46778374
Email paukrust@ous-hf.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints.


Recruitment information / eligibility

Status Recruiting
Enrollment 700
Est. completion date November 2020
Est. primary completion date August 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Adult patients, 18 years and above

2. Confirmed SARS-2-CoV-2 infection by PCR

3. Admitted to the hospital ward or the ICU

4. Subjects (or legally authorized representative) provides written informed consent prior to initiation of the study

Exclusion Criteria:

1. Severe co-morbidity with life expectancy <3 months according to investigators assessment

2. (Aspartate Transaminase/ Alanine Aminotransferase) ASAT/ALAT > 5 times the upper limit of normal

3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction

4. Known intolerance to the available study drugs

5. Pregnancy, possible pregnancy or breast feeding

6. Any reason why, in the opinion of the investigators, the patient should not participate

7. Subject participates in a potentially confounding drug or device trial during the course of the study

8. Prolonged QT interval (>450 ms)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxychloroquine
Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
Remdesivir
Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
Other:
(Standard of Care) SoC
The standard of care will be supplied to all patients not receiving a drug intervention.

Locations

Country Name City State
Norway Andreas Barratt-Due Oslo

Sponsors (1)

Lead Sponsor Collaborator
Oslo University Hospital

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Other Inflammatory and anti-inflammatory mediators as assessed in serum and plasma Throughout hospitalization
Other Markers of extracellular matrix remodeling Throughout hospitalization and 3 months after remission
Other Markers of endothelial activation Throughout hospitalization
Other Markers of platelet activation Throughout hospitalization
Primary In-hospital mortality All cause in-hospital mortality 3 weeks
Secondary Occurrence and duration of mechanical ventilation 3 weeks
Secondary Occurrence and duration of intensive care unit (ICU) treatment 3 weeks
Secondary Duration of hospital admittance 1 month
Secondary 28 Day mortality 3 weeks
Secondary Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen 3 weeks
Secondary Occurrence of co-infections 3 weeks
Secondary Occurrence of organ dysfunction 3 months
See also
  Status Clinical Trial Phase
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546776 - COVID-19 Persistence in Stool
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT05065827 - Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
Completed NCT04542915 - COVID-19-Related Health and Practices Among Dental Hygienists
Recruiting NCT04615052 - Home-based Exercise in COVID-19 Survivors N/A
Enrolling by invitation NCT04659486 - Adolescents With COVID-19/MIS-C at HCFMUSP N/A
Recruiting NCT04885452 - Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.
Completed NCT04516928 - Study of SARS-CoV2 Virus (COVID-19) Seroprevalence Among Lyon-Bron Military Health Schools Personnel
Completed NCT05063812 - Performance of a Remote Monitoring Program for Patients Diagnosed With COVID-19
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Recruiting NCT04565782 - Corona Virus Infection Among Liver Transplant Recipients
Completed NCT04550390 - Study of the Analytical Performance of Different Salivary Self-collection Methods for the Detection of COVID-19
Completed NCT04733625 - The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection N/A
Active, not recruiting NCT04517136 - Impact of Perceived Control on Operational Strain: a Study of COVID-19 Pandemic Caregivers and Military Personnel on Operational Missions
Recruiting NCT04476680 - Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion N/A
Completed NCT04839913 - Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
Completed NCT04514874 - Assessment of the Prevalence and the Impact of the COVID-19 Epidemic in the French Flight Crew in 2020
Terminated NCT04606563 - Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection? Phase 3
Completed NCT05234359 - The CHILD Cohort COVID-19 Add-On Study